Filing Flows › Alamar Biosciences (ALMR) › Q1 2026
Alamar Biosciences (ALMR) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 8, 2026
Alamar Biosciences (ALMR) reported revenue of $26.0M for the first quarter 2026 (Q1 2026), +99% from a year earlier. Operating margin was -47.4%, net loss $21.3M (81.9% of revenue).
Alamar Biosciences, Q1 2026: revenue $26.0M (+99% year over year), operating margin -47.4%, net loss $21.3M, operating cash flow −$20.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26.0M | — | +99% |
| Operating profit | −$12.3M | — | — |
| Net earnings | −$21.3M | — | — |
| Operating cash flow | −$20.3M | — | — |
What changed
Revenue was $26.0M in Q1 2026, up 99% year over year. Consumables was the largest line at 54% of revenue. Consumables added $8.9M year over year (up 178%), 69% of the total change.
Gross margin was 55.5%, up 6.7 points from a year earlier. Operating costs exceeded revenue by $12.3M, an operating margin of -47.4%. Operating expenses grew 79% against revenue growth of 99%. The fastest-growing cost line was SG&A (+108%). The quarter ended with a net loss of $21.3M.
Operating cash flow was −$20.3M. Non-cash charges added back $1.2M of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items used $1.7M. Capital expenditures of $600K exceeded it, leaving free cash flow of −$20.9M.
Questions
What was Alamar Biosciences' revenue in the first quarter 2026?
Alamar Biosciences (ALMR) reported revenue of $26.0M for the first quarter 2026 (Q1 2026), +99% from a year earlier.
Was Alamar Biosciences profitable in the first quarter 2026?
Operating loss was $12.3M (-47.4% of revenue) and net loss $21.3M.
Source: Alamar Biosciences 10-Q on SEC EDGAR.